Compare · GNPX vs MGTX
GNPX vs MGTX
Side-by-side comparison of Genprex Inc. (GNPX) and MeiraGTx Holdings plc (MGTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GNPX focuses on Biotechnology: Pharmaceutical Preparations, while MGTX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- MGTX is the larger of the two at $795.5M, about 356.9x GNPX ($2.2M).
- GNPX has been more active in the news (9 items in the past 4 weeks vs 8 for MGTX).
- MGTX has more recent analyst coverage (4 ratings vs 0 for GNPX).
- Company
- Genprex Inc.
- MeiraGTx Holdings plc
- Price
- -
- -
- Market cap
- $2.2M
- $795.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 9
- 8
- Recent ratings
- 0
- 4
Genprex Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.
Latest GNPX
- Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 10-Q filed by Genprex Inc.
- Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 8-K filed by Genprex Inc.
- Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
- SEC Form 8-K filed by Genprex Inc.
Latest MGTX
- PRESIDENT & CEO Alexandria Forbes gifted 24,100 units of Ordinary Shares and sold $523,900 worth of Ordinary Shares (62,000 units at $8.45) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 1,239,595 units (SEC Form 4)
- SEC Form 144 filed by MeiraGTx Holdings plc
- MeiraGTx Announces Oral Presentation at ObesityWeek 2026
- SEC Form S-3ASR filed by MeiraGTx Holdings plc
- SEC Form 10-Q filed by MeiraGTx Holdings plc
- MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
- MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
- CFO & COO Giroux Richard sold $557,200 worth of Ordinary Shares (56,000 units at $9.95) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF SCI OFCR, OPHTHALMOLOGY Naylor Stuart sold $294,292 worth of Ordinary Shares (27,659 units at $10.64) as part of a pre-agreed trading plan (SEC Form 4)